Clinical Trial: A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09)

U.S., June 12 -- ClinicalTrials.gov registry received information related to the study (NCT07642024) titled 'A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09)' on June 08.

Brief Summary: This trial is a registrational Phase II/III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in combination with osimertinib in resectable EGFR-mutant non-small cell lung cancer.

Study Start Date: June, 2026

Study Type: INTERVENTIONAL

Condition: Non-small Cell Lung Cancer

Intervention: DRUG: BL-B01D1

Administration by intravenous infusion for a cycle of 3 weeks.

DRUG: Osimertinib

Oral administration...